Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma - response to Moreau et al

Merav Leiba, Abraham Avigdor

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)604-605
Number of pages2
JournalBritish Journal of Haematology
Volume168
Issue number4
DOIs
StatePublished - 1 Feb 2015
Externally publishedYes

Keywords

  • Bortezomib, cyclophosphamide and dexamethasone
  • Bortezomib, thalidomide and dexamethasone
  • Induction therapy
  • Multiple myeloma

Cite this